相关实验视频

Updated: Jun 11, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

索福里丁化合物通过ROS/CaMKII通路的抗不律性和抗氧化作用的多方面的潜力

Shuai Sun¹, Fangdi Shi¹, Gang Zhao¹

¹Department of Cardiology, Shanxi Provincial People's Hospital, Taiyuan, 030001, China.

|September 30, 2024

概括

索福里丁 (SPN) 是一种天然类化合物,通过稳定心脏细胞和调节关键信号通路,显示出作为抗心律失常疗法的潜力. 对斑马鱼模型的进一步研究支持其在调节心率和基因表达方面的作用.

科学领域:

药理学药理学是指药理学的学科.
心血管研究研究心血管研究
自然产品自然产品

背景情况:

心律不整是全球主要的健康挑战,推动了对新型治疗剂的需求.
索福里丁 (SPN) 是一种来自中国传统草药的诺利西丁类化合物,具有经过记录的抗心律失常和抗氧化特性.
现有的抗心律失常治疗有局限性,需要探索新的化合物.

研究的目的:

调查Sophoridine (SPN) 在心脏细胞和动物模型中的抗心律不整的潜力.
阐明SPN作用的基础分子机制,包括其对活性氧物种 (ROS) 和CaMKII信号传递的影响.
评估SPN对对心脏发育和功能至关重要的基因的影响.

主要方法:

使用H9C2大鼠心肌细胞进行体外研究,以评估细胞活力和信号通路激活.
在不同的葡萄糖条件下诱导心室节律失常,以评估SPN的调节作用.
在体内实验中,利用斑马鱼模型检查心率调节和基因表达变化.
对线粒体衍生的ROS和CaMKII活性进行定量分析.

主要成果:

SPN 显示出显著的抗不律性作用,即使在高度 (100μg/ml) 中也保持心肌细胞活力.
在50和100μg/ml时,SPN治疗导致ROS和CaMKII信号的增加,这表明SPN在细胞防御机制中的作用.
葡萄糖波动通过ROS/CaMKII通路被确定为SPN诱导的腹腔失常的调节者.
斑马鱼研究证实了SPN对心率的调节影响,并揭示了关键心脏发育基因 (nppa,nppb,tnnt2a) 的转录性放松调节.

结论:

索福里丁 (SPN) 显示出有前途的抗失常性质,在心肌细胞中具有有利的安全性.
ROS/CaMKII通路与SPN的作用机制有关,特别是在葡萄糖波动的背景下.
SPN显示出作为心律失常的新型治疗剂的潜力,需要进一步的临床研究.

关键词:

抗心律失常的抗心律失常剂抗氧化剂是一种抗氧化剂.这就是ROSOS ROS.索福里丁 (Sophoridine) 是一种氨酸.斑马鱼是一种斑马鱼.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

相关概念视频

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...